Join date: May 15, 2022


Primer Premier 6 (Updated 2022)




Designing DNA Amplicons Using Primer Premier software to generate PCR primer sequences for the amplification of human α-globin gene Using Primer Premier software to design PCR primers The Best Software to Create PCR Primers in 2020 References Category:Bioinformatics software Category:Data analysis software Category:Molecular biology Category:Molecular biology softwareThe invention relates to the use of a combination of HMG-CoA reductase inhibitors, in particular fluvastatin, and prodrugs of cholesterol esterase for the preparation of compounds which inhibit cholesterol biosynthesis in mammal cells, as well as for the treatment of diseases characterized by an increased cholesterol biosynthesis. HMG-CoA reductase (3-hydroxy-3-methylglutaryl-coenzyme A reductase) catalyses the rate-limiting step in the biosynthesis of cholesterol. Thus, this enzyme reduces HMG-CoA to mevalonate. The HMG-CoA reductase inhibitors such as fluvastatin (U.S. Pat. No. 4,375,485, U.S. Pat. No. 4,346,227 and U.S. Pat. No. 4,444,784) and lovastatin (U.S. Pat. No. 4,231,938) also known as compactin and mevinolin, respectively, have been developed as drugs for lowering cholesterol and thereby reducing the risk of coronary heart disease (Hardman J. G., Miller D. J., Goodman W. M., Graham, F. R. Drugs, 15:283-315, 1988). However, the cholesterol biosynthesis inhibition by the HMG-CoA reductase inhibitors (HMG-CoA reductase IC.sub.50 approximately 10.sup.-6 M to 10.sup.-8 M) cannot be entirely attributed to the mere inhibition of HMG-CoA reductase, since the biosynthesis of cholesterol is also affected by other metabolic pathways in which a variety of rate-limiting enzymes are involved. For example, it has been found that the cholesterol biosynthesis pathway is also regulated by farnesyl-pyrophosphate synthetase (FPPS) (EP 383666, U.S. Pat. No. 5,545,646), geranylgeranyl-pyrophosphate (GGPP) synthetase (





Primer Premier 6 (Updated 2022)

More actions